{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:37:22Z","timestamp":1759333042927},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2005,4]]},"DOI":"10.1016\/j.neurobiolaging.2004.05.001","type":"journal-article","created":{"date-parts":[[2004,7,30]],"date-time":"2004-07-30T05:37:34Z","timestamp":1091165854000},"page":"449-453","source":"Crossref","is-referenced-by-count":27,"title":["A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"26","author":[{"given":"Federico","family":"Licastro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Chiappelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi M.E.","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noor","family":"Kalsheker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alistair","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Porcellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Salani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Franceschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Canal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB1","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0092-8674(88)90462-X","article-title":"Immunochemical identification of the serine protease inhibitor alpha-1-antichymotrypsin in the brain amyloid deposits","volume":"52","author":"Abraham","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S0197-4580(01)00302-5","article-title":"Reactive astrocytes and alpha-1-antichymotrypsin in Alzheimer\u2019s disease","volume":"22","author":"Abraham","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB3","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-III-R. 3rd revised ed. Washington (DC): American Psychiatric Association; 1987."},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/glia.440020605","article-title":"Patterns of gliosis in Alzheimer\u2019s disease and aging cerebrum","volume":"2","author":"Beach","year":"1989","journal-title":"Glia"},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1212\/WNL.44.2.227","article-title":"Inverse association of anti-inflammatory treatments and Alzheimer\u2019s disease","volume":"44","author":"Breitner","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB6","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/oxfordjournals.epirev.a036092","article-title":"Epidemiology of Alzheimer\u2019s disease","volume":"14","author":"Breteler","year":"1992","journal-title":"Epidemiol. Rev."},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB7","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB8","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1001\/archneur.58.3.449","article-title":"A method for estimating progression rates in Alzheimer\u2019s disease","volume":"58","author":"Doody","year":"2001","journal-title":"Arch. Neurol."},{"issue":"6","key":"10.1016\/j.neurobiolaging.2004.05.001_BIB9","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1073\/pnas.92.6.2313","article-title":"Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation","volume":"92","author":"Eriksson","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB10","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/jnnp.54.5.469","article-title":"Are alpha-1-antichymotrypsin and inter-alpha-trypsin inhibitor peripheral markers of Alzheimer\u2019s disease?","volume":"54","author":"Furby","year":"1991","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB11","doi-asserted-by":"crossref","first-page":"7611","DOI":"10.1073\/pnas.86.19.7611","article-title":"Brain interleukin-1 and S-100 immunoreactivity are elevated in Down\u2019s syndrome and Alzheimer\u2019s disease","volume":"86","author":"Griffin","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1750-3639.1998.tb00136.x","article-title":"Glial-neuronal interactions in Alzheimer\u2019s disease: the potential role of a \u201ccytokine cycle\u201d in disease progression","volume":"818","author":"Griffin","year":"1998","journal-title":"Brain Pathol."},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/1531-8249(200003)47:3<361::AID-ANA12>3.0.CO;2-N","article-title":"Association of early onset Alzheimer\u2019s disease with an interleukin-1-alpha gene polymorphism","volume":"47","author":"Grimaldi","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1006\/geno.1996.0158","article-title":"No genetic effect of alpha-1-antichymotrypsin in Alzheimer\u2019s disease","volume":"33","author":"Haines","year":"1996","journal-title":"Genomics"},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB15","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ng0895-486","article-title":"APOE 4 associated Alzheimer\u2019s disease risk is modified by alpha-1-antichymotrypsin polymorphism","volume":"10","author":"Kamboh","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB16","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1056\/NEJM198604103141506","article-title":"Medical progress: Alzheimer\u2019s disease","volume":"274","author":"Katzman","year":"1986","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.neurobiolaging.2004.05.001_BIB17","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.4049\/jimmunol.149.9.3059","article-title":"Alpha-1-antichymotrypsin inhibits the NADPH oxidase-enzyme complex in phorbol ester-stimulated neutrophil membranes","volume":"149","author":"Kilpatrick","year":"1992","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.neurobiolaging.2004.05.001_BIB18","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1074\/jbc.273.7.4112","article-title":"Oncostatin M and the interleukin-6 and soluble interleukin-6 receptor complex regulate alpha-1-antichymotrypsin expression in human cortical astrocytes","volume":"273","author":"Kordula","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00002093-199509020-00009","article-title":"Acute phase reactant alpha-1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer\u2019s disease","volume":"9","author":"Licastro","year":"1995","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB20","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0165-5728(98)00096-4","article-title":"Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer\u2019s disease correlate with activated astrocytes and are affected by APOE 4 genotype","volume":"88","author":"Licastro","year":"1998","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB21","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0002-9440(10)65186-3","article-title":"A role for apoE in regulating the levels of alpha-1-antichymotrypsin in the aging mouse brain and in Alzheimer\u2019s disease","volume":"155","author":"Licastro","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0165-5728(99)00226-X","article-title":"Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer\u2019s disease: peripheral inflammation or signals from the brain?","volume":"103","author":"Licastro","year":"2000","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB23","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/1531-8249(200009)48:3<388::AID-ANA16>3.0.CO;2-G","article-title":"Gene polymorphism affecting alpha-1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer\u2019s disease risk","volume":"48","author":"Licastro","year":"2000","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.neurobiolaging.2004.05.001_BIB24","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1586\/14737175.2.5.639","article-title":"Genomics of immune molecules: early detection of cognitive decline and new therapeutic interventions","volume":"2","author":"Licastro","year":"2002","journal-title":"Expert Rev. Neurotherapeutics"},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/372092a0","article-title":"Amyloid-associated proteins alpha-1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer \u03b2-protein into filaments","volume":"372","author":"Ma","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/00002093-199408030-00001","article-title":"Neuroimmune mechanisms in Alzheimer\u2019s disease pathogenesis","volume":"8","author":"McGeer","year":"1994","journal-title":"Alzheimer Dis. Assoc. Disord."},{"issue":"6","key":"10.1016\/j.neurobiolaging.2004.05.001_BIB27","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0197-4580(01)00289-5","article-title":"Inflammation, autotoxicity and Alzheimer disease","volume":"22","author":"McGeer","year":"2001","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB28","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Service Task Force on Alzheimer\u2019s Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB29","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0169-409X(02)00162-X","article-title":"Neuroinflammation and anti-inflammatory therapy for Alzheimer\u2019s disease","volume":"54","author":"Moore","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s004390100575","article-title":"Polymorphism in the alpha-1-antichymotrypsin (ACT) gene promoter: effect on expression in transfected glial and liver cell lines and plasma ACT concentrations","volume":"109","author":"Morgan","year":"2001","journal-title":"Hum. Genet."},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB31","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1212\/WNL.48.5.1313","article-title":"No association between the alpha-1-antichymotrypsin A allele and Alzheimer\u2019s disease","volume":"48","author":"Murphy","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB32","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0197-4580(94)90026-4","article-title":"Alpha-1-antichymotrypsin and IL-1beta are not increased in CSF or serum in Alzheimer\u2019s disease","volume":"15","author":"Pirtilla","year":"1994","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB33","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/0140-6736(93)91705-Q","article-title":"Apolipoprotein polymorphism and Alzheimer\u2019s disease","volume":"342","author":"Poirier","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB34","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0301-0082(97)00014-2","article-title":"The genetics of Alzheimer\u2019s disease","volume":"52","author":"Rubinsztein","year":"1997","journal-title":"Prog. Neurobiol."},{"issue":"8","key":"10.1016\/j.neurobiolaging.2004.05.001_BIB35","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1016\/S0021-9258(18)42729-9","article-title":"Regulation of neutrophil superoxide by antichymotrypsin-chymotrypsin complexes","volume":"267","author":"Schuster","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neurobiolaging.2004.05.001_BIB36","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1146\/annurev.bi.52.070183.003255","article-title":"Human plasma proteinase inhibitors","volume":"52","author":"Travis","year":"1983","journal-title":"Annu. Rev. Biochem."}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458004001952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458004001952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T01:44:26Z","timestamp":1705196666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458004001952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,4]]}},"alternative-id":["S0197458004001952"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2004.05.001","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2005,4]]}}}